News

5th Nov 2009 - AIMSPRO receives US orphan-drug designation for ALS

The US Government, through the Department of Health and Human Services, has designated AIMSPRO as an orphan-drug for the treatment of amyotrophic lateral sclerosis (ALS), with effect from 28 October 2009. ALS is the most prevalent type within the Motor Neurone Disease group of disorders.